Mitchell Goff, MD
Retina Specialist · Salt Lake City, UTNPI 1578595153
Payments from drug & device makers
Across 589 payments — averaging $2841.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$955K
- Eyepoint US, Inc.$293K
- Regeneron$225K
- Regeneron Healthcare Solutions, Inc.$132K
- Novartis$18K
- Bayer$13K
- plus $38K from 12 others
Across 4 payments — averaging $1756.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$55,13333%
- Speaking & faculty fees$87,78253%
- Travel & lodging$15,78810%
- Food & beverage$6,3204%
- Entertainment$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 170 | $954,857 |
| Eyepoint US, Inc. | 9 | $293,063 |
| Regeneron | 120 | $224,632 |
| Regeneron Healthcare Solutions, Inc. | 169 | $131,829 |
| Novartis | 6 | $18,103 |
| Bayer | 5 | $13,221 |
| AbbVie(2 entities) | 10 | $11,557 |
| Astellas Pharma US Inc | 34 | $10,916 |
| F. Hoffmann-la Roche AG | 2 | $5,953 |
| Genentech USA, Inc. | 37 | $4,263 |
| Alcon Research LLC | 2 | $4,200 |
| Harrow Eye, LLC | 8 | $433 |
| Alimera Sciences, Inc. | 7 | $139 |
| Biogen | 5 | $89 |
| Hoffmann-la Roche Limited | 1 | $46 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Optos, Inc. | 1 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,673,400 in reported general payments places this provider in the 85th percentile of 20 retina specialist providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $4,613 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,408 |
| Prednisolone Acetate | 43 | $1,386 |
| Latanoprost | 92 | $656 |
| Ketorolac Tromethamine | 20 | $517 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $256 |
| Timolol Maleate | 15 | $212 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Salt Lake City
- James HowardSalt Lake City$2.8M
- Robert KwunSalt Lake City$2M
- David FaberSalt Lake City$412K
- Rebekah GensureSalt Lake City$5K
- Kirk WinwardSalt Lake City$3K
- Eric BrintonSalt Lake City$3K
- Gregory BrintonSalt Lake City$1K
- Mano SwartzSalt Lake City$28
- Douglas MehrWest Jordan$34K
- Andrew DavisWest Jordan$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.